Objective. To assess the potential of metastasin S100A4 as a biological marker in patients with RA.
Introduction
RA is an inflammatory joint disease that affects 1% of the world population. If untreated, it leads to progressive joint destruction, functional disability and increased mortality. Recent population-based studies [1] have shown that although RA patients show no increase in total cancer risk, they have an increased risk of lymphoma and lung cancer. Research suggests that the relative risk for lymphoma in this population is dependent on RA severity [2] . Evaluation of a population-based cohort of patients with nonHodgkin's lymphoma showed an increased association between autoimmune disease and RA [3] . Furthermore, paraneoplastic syndromes may present with RA-like polyarthritis.
This reciprocal association between malignancy and autoimmune disease has been the focus of extensive research. It was demonstrated that RA patients with persistently active disease, high levels of inflammation and other factors associated with diseases severity (e.g. Felty syndrome) have increased risk of lymphoma [4, 5] . Research suggests that the use of immunomodulatory agents, synthetic DMARDs and biologic therapy may contribute to increased mutagenesis and concomitant cancer risk [68] . Viral infection and EBV infection in RA has been linked to the development of lymphoma [3, 9] . Increased EBV load and defective T-cell response have been reported in studies investigating the peripheral blood and bone marrow of RA patients [10, 11] . In contrast, elimination of antigen-presenting cells and autoreactive T cells by Fas-mediated mechanisms has been shown to prevent the development of systemic autoimmunity [12] .
Clinical evidence for the permissive role of chronic inflammation in tumour promotion has been confirmed in molecular studies of inflammation-associated cancer models [13, 14] . The transcription factor nuclear factor kB (NF-kB), the major regulator of pro-inflammatory cytokine and chemokine production, had emerged as an endogenous tumour promoter [1315] . Recent research has demonstrated that macrophages contribute to tumour survival, proliferation and invasion [16] , as well as to the development of erosive arthritis [17] . The synovial fibroblasts of RA patients have the ability to proliferate and to invade the surrounding tissues in a tumour-like fashion, leading to destruction of cartilage and underlying bone. This invasive RA synovia displays an increased expression of proto-oncogenes such as c-Myc and c-Ras [18] , and carcinoembryonic antigens [19] , as well as low activity of the tumour suppressor genes p53 and PTEN [20, 21] . High levels of the proto-oncogene survivin predicted gradual radiological destruction in a cohort of patients with early RA [22, 23] . The metastasis-promoting protein metastasin (S100A4) has recently been found to be overexpressed in RA synovial tissue, and may be implicated in the pathogenesis of arthritis [24] . S100A4 is a member of the S100 family of calciumbinding proteins. S100 family members have a wide range of intracellular functions, including the regulation of homeostasis, protein phosphorylation, cytoskeletal rearrangements and transcriptional activity [25, 26] . Extracellular functions include the regulation of cell proliferation and activation, apoptosis and chemotaxis. S100A4 is located intracellularly in a wide range of adult-differentiated cells, and forms homo-and heterodimers to exert its functional effects. S100A4 binds liprin-b1, methionine aminopeptidase, the p53 tumour suppressor protein, as well as proteins involved in cytoskeletal rearrangements and cell motility, such as F-actin, tropomyosin and the heavy chain of non-muscle myosin II [26] . Interaction between S100A4 and myosin-IIA regulates the assembly of myosin-II filaments, and enhances cell motility by promoting forward protrusions during chemotaxis. Interaction between S100A4 and p53 occurs in the C terminus of p53, and inhibits phosphorylation of protein kinase C. This leads to a general loss of p53 function and promotes the acquisition of an invasive phenotype [25] .
Compared with patients with OA, RA patients show an up-regulation of S100A4 in the circulation. This accumulates in SF and in synovial tissue [24, 27] being associated with the activity of RA [28] . Activation of S100A4 has been demonstrated in various proliferating cell types in the synovial edge, including fibroblasts, macrophages and neutrophils. A substantial amount of the SF S100A4 was present in its multimeric bioactive form. It has been hypothesized that S100A4 contributes to the invasive and tumour-like behaviour of RA synovium [27] . Articular chondrocytes from the cartilage of OA patients have been shown to release S100A4 following stimulation via IL-7-dependent activation of JAK/STAT signalling [29] . S100A4 then acts in an autocrine manner, and binds the receptor of advanced glycation end products (RAGE) to stimulate metalloproteinase release and chondrocyte proliferation [27, 30] .
The results of the present cross-sectional study of RA patients show that levels of S100A4 were increased in proportion to radiological damage and predicted further progression of radiographic damage. High S100A4 levels were associated with a poor clinical response to infliximab and high levels of antibodies to infliximab. The finding of a correlation between S100A4 and the levels of the proto-oncogene survivin and the differentiation protein Flt3 ligand suggests that these proteins represent a new cluster of biomarkers predicting radiological progress and poor treatment response in RA patients.
Patients and methods

Patient cohort
A cross-sectional cohort of 87 unselected RA patients (69 women, 18 men, aged 60 ± 12 years) attending the Rheumatology Clinic at Sahlgrenska University Hospital, Gö teborg, for regular infusions of infliximab (Remicade, Schering-Plough). The patients were consequently included in the study during the period between October 2008 to January 2009. The disease duration at inclusion was 16.8 ± 11.3 years and the patients had been treated with infliximab 32 ± 26 months. Demographic and clinical characteristics of the patients are presented in Table 1 . Infliximab treatment was provided intravenously, 200 mg every 8th week, and was combined with MTX in 81 patients, AZA in 3, chlorambucil in 1 and LEF in 1. All patients gave written informed consent and the study was approved by the Ethics Committee of the University of Gö teborg.
Disease activity
The DAS-28 was calculated after evaluating 28 joints for tenderness and swelling, and ESR [31] . Disease activity was categorized as remission (DAS-28 < 2.6) or active RA (DAS-28 > 3.5). The change in DAS-28 from the start of infliximab treatment (ÁDAS-28) was calculated and a clinical response to treatment was defined as ÁDAS-28 > 1.3 [32] .
Radiographic evaluation
The degree of radiographic joint damage in 72 patients was calculated from posterioranterior radiographs of the hands and feet obtained at inclusion in the study, using the Sharp method modified by van der Heijde www.rheumatology.oxfordjournals.org (vdHSharp) [33] . The vdHSharp score was presented as a total score (range 0448), an erosion score and a joint space narrowing score. A total vdHSharp > 50 characterized severe radiographic damage. Radiographs of hands and feet were taken before the start of infliximab treatment (52 patients) and at inclusion in the study (72 patients), after 32 ± 26 months of infliximab treatment (time interval 48 ± 27 months), which enable evaluation of radiographic progression during the treatment. The minimal detectable change of vdHSharp score was 5 [33] . A change of vdHSharp score between the two sets of radiographs >5 indicated radiographic progression.
Blood sampling
Blood samples were obtained at inclusion in the study. Serum was prepared from clotted whole blood drawn from the cubital vein, centrifuged at 800 g for 15 min, aliquoted and stored at À20 C until use. Samples were coded and analysed by investigators blinded for the clinical and radiological data.
Detection of serological markers
Serum S100A4 levels were measured in samples diluted 1 : 200 by an ELISA (KA0092, Abnova, Taipei City, Taiwan), with a detection limit of 10 ng/ml. COMP levels were measured by an ELISA kit from Anamar (Lund, Sweden) with a sample dilution of 1 : 10 and a detection limit of 0.9 IU/ml. C-telopeptide of type I collagen (CTX-I) was measured by an ELISA (the IDS serum Crosslaps, Immunodiagnistics Service, Boldon, UK) in undiluted samples with a detection limit of 0.11 ng/ml. MMP-3 levels were measured by an ELISA using a pair of matched antibodies (DY513, R&D Systems, Minneapolis, MN, USA) in samples diluted 1 : 100 with a detection limit of 3 ng/ml. ESR was measured by the Westergren method, and CRP was measured by nephelometry at the hospital laboratory. IL-6 levels were measured by a bioassay using cell line B9, which is dependent on IL-6 in its growth [34] , with a sample dilution of 1 : 50 and a detection limit of 50 pg/ml. Survivin levels were measured in samples diluted 1 : 10 using a sandwich ELISA and a pair of matched antibodies (DY647, R&D Systems), with a detection limit of 1 ng/ml. Flt3 ligand levels were measured by an ELISA using a pair of matched antibodies (DY308, R&D Systems) in undiluted samples with a detection limit of 0.03 ng/ml. Insulin-like growth factor 1 (IGF-1) levels were measured by an ELISA using a pair of matched antibodies (DY291, R&D Systems) in samples diluted 1 : 25, with a detection limit of 1 ng/ml.
Statistical evaluation
The correlation between variables was tested by Spearman's test to evaluate the relationship between all available variables and S100A4 levels and/or radiographic progression. Any two factors having a correlation coefficient >0.3 were investigated for collinearity. S100A4 values were dichotomized using mean serum levels in healthy controls as low (<200 ng/ml) and 10-fold excess as high (>2000 ng/ml). Proportions of patients with severe radiological damage (vdHSharp > 50), progress of radiological damage (change of vdHSharp > 5), patients with active RA (DAS-28 > 3.5), patients in remission (DAS-28 < 2.6) and responders to infliximab treatment (change of DAS-28 > 1.3) were calculated. Differences in groups were assessed by the MannWhitney U-test, and sensitivity and specificity of calculations were performed using 2 Â 2 table analysis. Univariate analyses of the association of S100A4 and other baseline clinical and demographic variables with radiological and clinical outcome were performed. Multiple logistic regression analyses with backwards elimination were performed, adjusting for those demographic and baseline clinical and radiological variables that were significantly (P < 0.1) associated with the outcomes in the univariate analyses. The criterion for elimination of a variable from the model was set at P < 0.05. The predictive probability of S100A4 for clinical and radiological outcome was analysed by 2 Â 2 tables and odds ratios (ORs), sensitivity, specificity, and positive and negative predictive values were calculated. All tests were two-tailed and conducted with 95% confidence. Statistical analyses were performed using StatView and SPSS software.
Results
High levels of S100A4 were associated with severe radiographic damage and its further progression during infliximab treatment
The vdHSharp scores at inclusion were directly correlated with the levels of S100A4 (r = 0.38, P = 0.001). This correlation was more pronounced in females (r = 0.347, P = 0.027; ÁvdHSharp, r = 0.376, P = 0.017) compared with males [r = 0.209, not significant (n.s.); ÁvdHSharp, r = 0.294, n.s.]. Patients with S100A4 levels >200 ng/ml had higher total vdHSharp scores than patients with S100A4 levels <200 ng/ml (45 ± 40 vs 63 ± 67, P = 0.043). This applied to both the erosive score, which was 47% higher, and the joint space narrowing score, which was 34% higher in patients with high S100A4 levels. Consequently, the proportion of individuals with severe radiographic damage at inclusion (vdHSharp >50) was 2-fold higher among patients with S100A4 levels >200 ng/ ml (60 vs 29%, P = 0.048, Fig. 1A ). An association between high levels of S100A4 and severe radiographic damage at inclusion was observed (OR = 3.40, P = 0.025, Table 2 ).
Progression of radiographic damage increased gradually with the level of S100A4, and reached a frequency of 75% in patients with high S100A4 (Fig. 1B) . This association was found in male and female patients. Patients with S100A4 >200 ng/ml showed a significant increase in vdHSharp scores during infliximab treatment, whereas patients with S100A4 <200 ng/ml did not (ÁvdHSharp: 13.4 ± 19.9 vs 4.6 ± 8.0, P = 0.042, Fig. 1C , supplementary Table 1 , available as supplementary data at Rheumatology Online). Additionally, the mean change in vdHSharp scores in patients with low S100A4 was under the minimal detectable level. Radiological damage progression was correlated with vdHSharp prior to infliximab treatment (r = 0.32, P = 0.036).
Logistic regression analysis revealed that a high level of S100A4 was the risk factor for radiographic progression [OR (95% CI) 3.53 (1.00, 14.6), P = 0.05, positive predictive value (PPV) 0.42]. Correction of the change in vdHSharp score was performed to account for confounding parameters such as disease duration, gender, DAS-28 at inclusion, concomitant MTX treatment and time interval between the radiographic investigations. The vdHSharp score prior to infliximab treatment was identified as the   FIG. 1 Clinical relevance of S100A4 for disease activity, radiological progression and treatment response in RA. Patients were stratified in groups with low (<200 ng/ml, n = 28), medium (2012000 ng/ml, n = 34), and high (>2000 ng/ml, n = 25) serum levels of S100A4. Association of S100A4 levels to radiographic changes [Sharpvan der Heijde (svH) score] (A) and its progression during infliximab treatment (B, C). Association of S100A4 levels to disease activity (DAS-28) (D), RA remission (E) and the change of DAS-28 during infliximab treatment (F). Levels of S100A4 in relation to the cumulative dose of infliximab and patient gender (G). Association between high survivin levels and levels of S100A4 (H). High levels of S100A4 were associated with non-response to infliximab and the development of anti-infliximab antibodies DAS-28 at inclusion was correlated with S100A4 levels (r = 0.206, P = 0.057). Stratification of patients according to the level of S100A4 showed that patients with low S100A4 also had lower DAS-28 compared with patients with S100A4 >200 ng/ml (2.8 ± 1.1 vs 3.6 ± 0.9, not significant). Consequently, the patients with active disease (DAS-28 > 3.5) were frequent in the high S100A4 group (Fig. 1D) , most patients in remission were in the low S100A4 group (61%), and the rate of remission was reduced more than 2-fold if S100A4 levels were >200 ng/ml (26 and 20%, respectively, P = 0.008, Fig. 1E ). The change in DAS-28 during infliximab treatment (ÁDAS-28) was inversely correlated with the level of S100A4, and gradually reduced with increasing levels of S100A4. The rate of infliximab response was highest in the group with low S100A4, and reached 75% (P = 0.015, Fig. 1F ). ÁDAS-28 was significantly lower in patients with high S100A4 compared with patients with low S100A4 (1.5 ± 1.5 vs 2.3 ± 1.6, P = 0.050). Infliximab responders had lower levels of S100A4 compared with non-responders (ng/ml: 1179 ± 1529 vs 2297 ± 1817, P = 0.026). Multiple regression analysis showed that low S100A4 predicted response to infliximab (PPV 0.48, OR = 2.68, P = 0.049, Table 2 ), and the ability to achieve remission (PPV 0.77, OR = 4.01, P = 0.0047), whereas high S100A4 was associated with non-response to infliximab (OR = 4.63, P = 0.003) and the development of anti-inflixmab antibodies during treatment (OR = 6.24, P = 0.003).
Levels of S100A4 showed a sex-related dimorphism
Comparison of S100A4 levels in female and male patients showed that S100A4 levels were significantly higher in men (ng/ml: 2054 ± 1955 vs 1281 ± 1281, P = 0.046). Specific correlations with S100A4 also differed between male and female patients. In male patients, S100A4 was strongly correlated with DAS-28 at sampling (r = 0.74, P = 0.002) and to the change in DAS-28 during treatment with infliximab (r = À0.35). No such correlation was observed in female patients. Male patients had significantly lower DAS-28 prior to infliximab treatment (P = 0.055) and at inclusion (P = 0.00005). The lower DAS-28 observed in male patients was attributable to a significantly lower number of tender joints and lower ESR values (supplementary table 2 , available as supplementary data at Rheumatology online). No sex differences were observed for radiographic change (as measured by vdHSharp score) at sampling, ÁvdHSharp score during infliximab treatment or ÁvdHSharp/month. Levels of S100A4 were inversely correlated with the cumulative dose of infliximab (r = À0.304, P = 0.0014), i.e. S100A4 levels decreased with increasing doses. This correlation was more pronounced in female patients (r = À0.33, P = 0.0015, Fig. 1G ). In male patients, no correlation was found between the levels of S100A4 and the duration of infliximab treatment. However, S100A4 levels were correlated with ESR (r = 0.505, P = 0.037) and CRP (r = 0.302), and inversely correlated with the levels of COMP (r = À0.368) and CTX-I (r = À0.418, P = 0.084). Female patients with high S100A4 levels had significantly higher levels of survivin (P = 0.0001) and Flt3 ligand (P = 0.037) and lower levels of IL-6 (P = 0.015) compared with females with S100A4 levels <1999 ng/ml (Table 3) . Gender differences between clinical and laboratory variables of the RA cohort are shown in Table 3 and supplementary table 2 , available as supplementary data at Rheumatology online.
Correlation between S100A4 and the proto-oncogene survivin S100A4 levels showed a strong correlation with the levels of survivin (r = 0.71, P = 0.0001). This correlation was observed in female and male patients (r = 0.759 and r = 0.533, respectively). Survivin levels were up to 20-fold higher in patients with S100A4 levels >2000 ng/ml compared with patients with lower S100A4 levels (Fig. 1H , Table 3 ). The PPV of high S100A4 levels for concomitant high levels of survivin was 0.88. The inclusion of high levels of survivin as a confounding factor in multivariate regression analysis revealed that high levels of S100A4 were associated with severe radiographic damage (vdHSharp > 50), and this association was dependent on survivin levels. High levels of S100A4 in female patients were also associated with high levels of Flt3 ligand (OR = 2.73, P = 0.04, Table 2 ). Regression analysis showed that the associations between S100A4, radiographic damage and radiographic damage progression were independent of the high levels of Flt3 ligand.
Discussion
The present study showed that S100A4 was associated with radiographic damage in RA patients and had predictive value with respect to radiographic damage progression and clinical response to infliximab treatment. The study was cross-sectional and included an unselected cohort of RA patients who were treated with infliximab at a single rheumatology clinic. This RA cohort was representative, since 79% were women, the mean age was 60 years, 93% were receiving concomitant treatment with MTX and 60% showed clinical response to the treatment with TNF inhibitor. These figures are consistent with the characteristics of RA patients treated with biological DMARDs described in RA registers in Europe [35] . Disease duration in the present RA cohort was 16 years, which is significantly longer than that of the total RA population treated with biological DMARDs in Sweden [1, 36] . S100A4 showed no correlation with disease duration, and adjustment for this parameter in the regression analysis had no effect on the results of the statistical analysis. Additionally, disease duration was similar after stratification for S100A4 levels. Levels of S100A4 were associated with radiographic damage in the joints of the hands and feet at inclusion TABLE 3 Gender differences between serological markers of RA patients dichotomized by the levels of S100A4
Women Men
<1999 ng/ml >2000 ng/ml <1999 ng/ml >2000 ng/ml n = 53 n = 16 n = 9 n = 9 S100A4, ng/ml 311 (01939) 4180 (22434445) and with radiographic damage progression during infliximab treatment. Other factors of importance to radiographic progression were radiographic damage prior to infliximab treatment, disease duration >5 years and being a female aged >51 years. These findings are consistent with results obtained in other cohorts [1, 35, 36] . The radiographic progression in the present cohort was surprisingly limited, despite an interval of 48 months between examinations. This observation suggests that radiographic progression occurs close to the commencement of infliximab treatment and levels off during treatment, or that it occurs in a defined group of RA patients within the treated cohort, namely in patients with high S100A4 levels. A substantial proportion of the study patients (38%) had severe radiographic damage prior to infliximab treatment, a feature that is associated with irreversible functional disability [31] . This may explain, at least in part, the absence of any correlation between a clinical response to infliximab treatment and an increase in radiological damage during the treatment period. A relationship between radiographic damage and S100A4 levels was not observed for other biomarkers of bone and cartilage metabolism (COMP, CTX-I and MMP3) of value in RA patients [3740] . In the present cohort, S100A4 levels showed sex-related dimorphism. Associations between S100A4 and COMP and CTX-I were only observed in male patients, who comprised 21% of the patient cohort. This provides a potential explanation for the absence of any correlation between these biomarkers and radiographic damage. S100A4 levels were directly correlated with the level of active disease and inversely correlated with the rate of remission. Correction for confounding factors such as age, gender and disease duration confirmed the predictive value of S100A4 for clinical response to infliximab. Decreased disease activity and complete remission have been proposed as the primary goals in the management of RA patients [41] . This leads to important clinical and functional benefits secondary to reduced joint damage [42, 43] . Thus the finding of an association between S100A4 levels and both clinical activity and treatment response renders the S100A4 level a useful parameter in the evaluation of RA patients. Changes in the prescription pattern of biological DMARDs and the tendency to commence biological treatment in patients with shorter disease duration and lower disease activity [36, 44] increase the value of biomarkers such as S100A4 in the management of RA patients.
Levels of S100A4 were closely correlated with the levels of the proto-oncogene survivin, which has recently been shown to have predictive value for radiological damage in early RA [23] . S100A4 was also associated with the levels of Flt3 ligand, a differentiation factor that was recently found to have predictive value in the preclinical diagnosis of RA [45] . Both of these proteins are important regulators of cell proliferation, differentiation and motility [46] . Survivin and Flt3 ligand are clearly associated with the presence of autoantibodies to CCPs and RF, which are established prognostic parameters of the functional, radiographic and clinical outcome in RA patients [23, 45] . The clinical effect of infliximab may be adversely affected by the presence of anti-infliximab antibodies [4749] . In the present study, high levels of S100A4 were clearly associated with both factors. Although the predictive value of S100A4 for radiological progression and clinical response appeared to be independent of survivin and Flt3 ligand, accumulation of these proteins in the present cohort of RA patients with severe joint destruction and poor response to treatment with biological DMARDs suggests that these proteins represent a new cluster of biomarkers in RA patients.
Rheumatology key messages
. S100A4 levels are increased in proportion to radiographic damage and its progression in RA patients. . High S100A4 levels were associated with a poor clinical response to infliximab. . S100A4, survivin and Flt3 ligand form a cluster of predictive biological markers in RA.
